Celon Pharma

Celon Pharma EBITDA per Employee

The EBITDA per Employee of Celon Pharma (CLN.WA) as of Oct 27, 2026 is -110,647.17 PLN. In the previous year, EBITDA per Employee was 29,333.33 PLN — a change of -477.21% (lower).

EBITDA per Employee

-110,647.17PLN

YoY

-477.21%

Last updated:

EBITDA per Employee of Celon Pharma is 2025 -110,647.17 PLN. EBITDA per Employee of Celon Pharma was 2024 29,333.33 PLN. It decreases by -477.21% lower compared to the previous year.

The Celon Pharma EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
102,973.63 PLN
Jan 1, 2019
53,642.84 PLN
Jan 1, 2020
58,497.08 PLN
Jan 1, 2021
54,206.63 PLN
Jan 1, 2022
-50,031.19 PLN
Jan 1, 2023
44,393.76 PLN
Jan 1, 2024
29,333.33 PLN
Jan 1, 2025
-110,647.17 PLN
The Celon Pharma EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-110,647.17PLN-477.21%
29,333.33PLN-33.92%
44,393.76PLN-188.73%
-50,031.19PLN-192.30%
54,206.63PLN-7.33%
58,497.08PLN+9.05%
53,642.84PLN-47.91%
102,973.63PLN+22.14%
84,310.98PLN-28.40%
117,756.37PLN+9.11%
107,926.37PLN+89.53%
56,943.58PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Celon Pharma Stock analysis

What does Celon Pharma do? Celon Pharma SA develops and manufactures generic drugs for cancer, neurological diseases, diabetes, and metabolic disorders. Its product portfolio includes pills like Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder Salmex. The company operates through its research center focused on oncology, neurology, and inflammatory and metabolic diseases. As a subsidiary of Glatton sp z o o, Celon Pharma SA serves healthcare providers and patients seeking affordable treatment options for chronic conditions. Celon Pharma SA's revenue comes from selling its generic drug portfolio to pharmacies, hospitals, and healthcare institutions. The firm's products target patients with conditions such as cancer, neurological disorders, and diabetes, where cost-effective alternatives are in demand. Glatton sp z o o, the parent company, likely oversees strategic direction and resource allocation for Celon Pharma SA's operations. The company's focus on generic drugs positions it within the pharmaceutical market segment for affordable treatments. Its research center develops new formulations within therapeutic areas like oncology and neurology, supporting ongoing product innovation. Celon Pharma SA's product lineup, including inhalation powder Salmex and pill-based treatments, caters to specific medical needs across multiple disease categories. Celon Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celon Pharma stock

EBITDA per Employee of Celon Pharma is -110,647.17 PLN in 2025.

EBITDA per Employee of Celon Pharma changed from 29,333.33 PLN to -110,647.17 PLN, representing a -477.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Celon Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Celon Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Celon Pharma

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Celon Pharma